Seamus Fernandez
Stock Analyst at Guggenheim
(3.58)
# 888
Out of 4,761 analysts
92
Total ratings
50%
Success rate
7%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $13.02 | - | 1 | Feb 10, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $34.55 | - | 7 | Feb 10, 2025 | |
| CDTX Cidara Therapeutics | Initiates: Buy | $33 | $21.54 | +53.20% | 1 | Nov 8, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $89.50 | +45.25% | 13 | Nov 6, 2024 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $36.64 | - | 2 | Oct 31, 2024 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Buy | $70 | $56.07 | +24.84% | 1 | Oct 21, 2024 | |
| TENX Tenax Therapeutics | Initiates: Buy | $16 | $6.75 | +137.04% | 1 | Oct 14, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $44 | $10.88 | +304.41% | 1 | Oct 8, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $884 → $1,030 | $873.68 | +17.89% | 14 | Aug 16, 2024 | |
| HLVX HilleVax | Downgrades: Neutral | n/a | $1.83 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.43 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $55 | $7.28 | +655.49% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $17.77 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $9.56 | +234.73% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $65 | $79.74 | -18.49% | 2 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $23.77 | +110.39% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $55.83 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $88.08 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $109.35 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.19 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $128.60 | -79.00% | 4 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $2.24 | +2,310.71% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $22.46 | +100.36% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $74.22 | -48.80% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $26.30 | +44.49% | 3 | Jan 31, 2018 |
Arcutis Biotherapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.02
Upside: -
Apogee Therapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $34.55
Upside: -
Cidara Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $33
Current: $21.54
Upside: +53.20%
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $89.50
Upside: +45.25%
GSK plc
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $36.64
Upside: -
Rhythm Pharmaceuticals
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $56.07
Upside: +24.84%
Tenax Therapeutics
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $6.75
Upside: +137.04%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $44
Current: $10.88
Upside: +304.41%
Eli Lilly and Company
Aug 16, 2024
Maintains: Buy
Price Target: $884 → $1,030
Current: $873.68
Upside: +17.89%
HilleVax
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.83
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.43
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $56 → $55
Current: $7.28
Upside: +655.49%
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $17.77
Upside: -
Mar 7, 2023
Initiates: Buy
Price Target: $32
Current: $9.56
Upside: +234.73%
Feb 28, 2023
Maintains: Buy
Price Target: $66 → $65
Current: $79.74
Upside: -18.49%
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $23.77
Upside: +110.39%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $55.83
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $88.08
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $109.35
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $5.19
Upside: -
Nov 15, 2018
Initiates: Outperform
Price Target: $27
Current: $128.60
Upside: -79.00%
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $2.24
Upside: +2,310.71%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $22.46
Upside: +100.36%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $74.22
Upside: -48.80%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $26.30
Upside: +44.49%